Horizon Therapeutics Public Limited Co (fka HZNP)

[Investor100]

Horizon Pharma's CEO Discusses Q3 2013 Results - Earnings Call Transcript ( November 8th,2013)

http://seekingalpha.com/article/1823202-horizon-pharmas-ceo-discusses-q3-2013-results-earnings-call-transcript

Some Highlights:

We delivered third quarter total net sales of $26.2 million, an increase of a 114% versus the second quarter of 2013. We also exited the quarter with approximately $58.7 million in cash and cash equivalent versus $69.3 million at the end of the second quarter. In the third quarter DUEXIS continued to demonstrate momentum with total prescriptions increasing approximately 18% versus the second quarter of 2013 and total net sales of DUEXIS is $23.5 million, an increase of a 122% versus the second quarter of 2013 with current annual net sales at a run rate of greater than $94 million.

So to-date, almost 20,000 physicians have written prescriptions for DUEXIS, with the majority of scripts being written by primary care physicians, followed by orthopedic surgeons and rheumatologists. We are pleased with the continued productivity of our sales force as measured on our prescriptions per representative basis. Additionally, we have seen from Q2 to Q3 an average increase of 14%, the number of writers on a weekly basis.


Turning to RAYOS, net sales in the third quarter were $2 million an increase of over 250% versus the second quarter of 2013. We are encouraged by the feedback and growing acceptance of RAYOS by both rheumatologists and patients. We recently presented data at the America College of Rheumatology meeting that patients of arthritis treated with the RAYOS at bed time had significant and sustained improvement in the morning symptoms for the one-year duration study as compared to group of patients treated with immediate release Premizone given in the waking hours.